Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Gliknik (Baltimore, MD), a clinical-stage biotechnology company focused on treatments for cancer and autoimmune diseases, closed a $4.9M Series B financing. Participants include Baxter Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Sensors for Medicine and Science (Germantown, MD) a commercial-stage device company focused on implantable, long- term continuous glucose monitoring, closed a $54.1M million in Series D financing. Participants include Delphi Ventures, New Enterprise Associates, HealthCare Ventures, Anthem Capital and Greenspring Associates.

NovaSom (Glen Burnie, MD) a commercial-stage medical device company focused on the diagnosis of obstructive sleep apnea, closed a $35M Series F financing. Participants include Safeguard Scientifics, TPG Biotech and Quaker BioVentures.

Ocimum Biosolutions (Gaithersburg, MD) a commercial-stage integrated genomics company focused on sample data analysis and management, closed a $8M Series C financing. Participants have included International Finance Corp. and Kubera Partners.

OpGen (Gaithersburg, MD) a commercial-stage genomics device company focused on optical mapping combining strain typing and sequencing, closed a $17M Series B round financing. Participants include jVen Capital, CHL Medical Partners, Highland Capital Partners, Mason Wells Biomedical and Versant Ventures.

OriGene Technologies (Rockville, MD) a commercial-stage gene-based reagent product company focused on cDNA and shRNA clone collections, purified human proteins, monoclonal antibodies, human tissues, multiplex assay products, antigen standards and IHC slides, closed a $16M Series B financing. Participants include IDG-Accel, SBI Ven Capital, TH Venture Capital Enterprise, Zero2IPO, Morningside and President International Development Corp..

Zyngenia (Rockville, MD) a pre-clinical stage biotherapeutics company focused on multi-specific antibodies for oncology and autoimmune disorders, closed a $10M Series A financing. Particpants include New Enterprise Associates. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

GlycoMimetics (Gaithersburg, MD) a clinical-stage small molecule glycobiology company focused on cancer, inflammation and infectious disease, closed a $38M Series C financing. Participants include Genzyme Ventures, New Enterprise Associates, Novartis Venture Fund, Anthem Capital Management and Alliance Technology Ventures. A more detailed company profile recently appeared on Life Science Deal Flow [HERE].

Arginetix (Baltimore, MD) a preclinical-stage pharmaceutical company focused on the small molecule inhibition of arginase for pulmonary arterial hypertension, closed a $4.6M Series B financing. Participants include Quaker BioVentures, MedImmune Ventures, Red Abbey Venture Partners, Maryland Health Care Product Development Corp. and Acidophil.

Sleep Solutions (Glen Burnies, MD) a commercial-stage medical device and diagnostics company focused on obstructive sleep apnea, closed a $20M Series F financing. Participants include Quaker BioVentures, Johnson & Johnson Dev Corp., TPG Growth, MedVenture Associates, Emergent Ventures and Lava Ventures.

Profectus BioSciences (Baltimore, MD) a clinical-stage biopharmaceutical focused on the development of vaccines for chronic viral infections, closed a $5M Series C financing. Participants include Cross Atlantic Capital Partners.

Zephyr Technology (Annapolis, MD) a commercial-stage device company focused on real-time monitoring of human of physiological and biomechanical conditions, closed a $2M Series B financing. Participants include Motorola Ventures.

GetWellNetwork (Bethesda, MD) a commercial stage telemedicine provider of interactive patient care solutions, closed a $10M Series C financing. Participants include Johnson & Johnson Development Corp., Valhalla Partners, Grosvenor Funds, Point Judith Capital and Village Ventures.

  

to top of page...